Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Conditioning HSCT for Hemoglobinopathies
NCT00153985Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2004
- Primary completion
- Mar 2008
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan, fludarabine and alemtuzumab in sickle cell disease (SCD) and thalassemia, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy at 3 years. Started Mar 2004; status: completed.
02
Drugs
busulfanfludarabinealemtuzumab
03
Conditions
sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT00153985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153985.